Clinical trial
CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's…
NCT00374179 · Adnexus, A Bristol-Myers Squibb R&D Company, Industry · Completed
Key facts
| NCT number | NCT00374179 |
|---|---|
| Title | CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma |
| Official title | A Phase 1, Escalating Dose Study of CT-322, a VEGFR-2 Antagonist, as Monotherapy in Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma |
| Lead sponsor | Adnexus, A Bristol-Myers Squibb R&D Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | CT-322 |
| Enrollment | 40 |
| Start date | Aug 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Sep 11, 2006 |
| Last update posted | Feb 24, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: